{"id":920889,"date":"2025-12-18T09:03:51","date_gmt":"2025-12-18T14:03:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/"},"modified":"2025-12-18T09:03:51","modified_gmt":"2025-12-18T14:03:51","slug":"eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/","title":{"rendered":"\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>BriaCell\u2019s Phase 3 clinical trial in metastatic breast cancer featured as \u201cclinical trial to watch in 2026\u201d<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>BriaCell anticipates reporting top line data as early as H1-2026<\/em><br \/>\n          <\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, Dec.  18, 2025  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its Phase 3 Bria-IMT\u2122 clinical trial in metastatic breast cancer has been prominently and independently featured in the Nature Medicine Year In Review\u2019s publication, \u201c<em>Eleven clinical trials that will shape medicine in 2026<\/em>\u201d<sup>1<\/sup>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v6Mt-VoyOIZQ1F5yV44PQgyGjY1US6xAttGAPA-nr7fXzRyNey5UAx-fKQPveRbSZG1dCThVghrY_bz3yiFMMxocF9gr8MKIk0goP4W84W9mM3GkDAyHgSFwZitYtxgL\" rel=\"nofollow\" target=\"_blank\">linked here<\/a>.<\/p>\n<p align=\"justify\">As quoted in the Nature Medicine feature, Dr. Sara A. Hurvitz, MD, FACP, stated: \u201cThe BRIA-ABC trial is an exciting study focused on people living with metastatic breast cancer. Even though cancer care has come a long way, metastatic breast cancer is still rarely curable, and only a small fraction of patients benefit long-term from current immunotherapy or targeted treatments. That is why this trial was designed \u2014 to see if a new cell-based immunotherapy, called Bria-IMT, can actually improve outcomes for people who have already gone through many prior treatments.\u201d<\/p>\n<p align=\"justify\">\u201cWhat really sets BRIA-ABC apart is how inclusive it is. It welcomes individuals with all breast cancer subtypes, including patients who cannot work but are able to take care of themselves \u2014 and those with brain metastases and people who have already had extensive prior treatments, even antibody\u2013drug conjugates or checkpoint inhibitors. Plus, it uses a real-world comparator arm, making the results much more meaningful for everyday clinical practice.\u201d Dr. Sara A. Hurvitz holds the Smith Family Endowed Chair in Women\u2019s Health at the Fred Hutchinson Cancer Center, Seattle, WA, USA.<\/p>\n<p align=\"justify\">BriaCell anticipates reporting top line data as early as H1-2026.<\/p>\n<p align=\"justify\">BriaCell\u2019s pivotal Phase 3 clinical study is evaluating BriaCell\u2019s lead clinical candidate, Bria-IMT, plus immune check point inhibitor versus physician\u2019s choice in <u>a<\/u>dvanced metastatic <u>b<\/u>reast <u>c<\/u>ancer (Bria-ABC).<\/p>\n<p align=\"justify\">BriaCell <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E-LhhUTR5aN2_iuhu7QYT-0-lYJUfl29TDLdejbsm1MI2gnuWjfb8YuiOQ24dcu70Xn8rLeD9MzI7a6mdNdPuN2OHzupq6s6n2gfUwvrt964SB7kdCOwLoLTgBDLvsU9DcIQgmuW164mplT0P761b8BqTXIsjy-NwINaXTGwwls=\" rel=\"nofollow\" target=\"_blank\">recently reported<\/a> its Phase 3 clinical study has screened more than 230 patients and enrolled over 160 patients to date. Interim data will be analyzed once 144 patient events (deaths) occur. This interim analysis will evaluate overall survival (OS) as the primary endpoint, comparing patients treated with the Bria-IMT combination regimen to those receiving physician\u2019s choice therapy. Positive results from this pivotal study could support full approval and marketing authorization of Bria-IMT for patients with metastatic breast cancer. The Bria-IMT combination regimen has been granted FDA Fast Track designation.<\/p>\n<p align=\"justify\">For additional information on BriaCell\u2019s pivotal Phase 3 study, please visit ClinicalTrials.gov <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AveY_lMN1cvLcNXxhDuc_LcjML5ScSjvvRlIad2bLKQb4Rn9931re1G4F3AdGUkfRuDixgJFvFRQHF1imibEwuyUmchsgs2ffsnjEp5Qv55OzSlrl_s6mmI3LBYewcw-\" rel=\"nofollow\" target=\"_blank\">NCT06072612<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VxjuPGHt3jiHCG2tkkHVOoVWrdzVKBR64rLh5Z3R2W2ssKNNHWYYPP3wPJA08ZIrXnfztM4zaPn5frqGManD-lyiEiOaQSCYRfFwj3eV1vM=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about anticipated timelines for data reporting, interim analysis, regulatory submissions, and the results and conclusions contained in this press release, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company&#8217;s most recent Management\u2019s Discussion and Analysis, under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company&#8217;s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR+ at <strong><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hpW3NcVrH0bJO_EPE_aJeyV7nzCgmGivGOPGHz7vqJkM4c18oXl88Cp0C2PxQBOpJMXkdbRY5Z--tmnAbO7KAHhzNP2YAMnEW8R-QRHjtZo=\" rel=\"nofollow\" target=\"_blank\">www.sedarplus.ca<\/a><\/u><\/strong>\u00a0and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hpW3NcVrH0bJO_EPE_aJe1YGl2ZjEUjQKWcoj6AoqieniWSqlLtVIv4qM_eOJ28imTxEjt1xyhdmQ_Uj-H3Mdw==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7Gr8Lsvznv95Ij8LAKxDD4AxRyk2MAtJkRBqga-_kWuyo1uA_Biq0DabT2mxAcNinUfZozxrydK6kJ5F_Twj9q1xtmz12rzwP4Daf7h0a34=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RpLNGi-s75fxE93IsZ7qi9x0wur2fG3ek2B8NyMbBHmagdsm4BN02x2FtTAoTcDZMKWynOTjZzXZ0AfH2vdf6x2MrDM3fPr3Ft8SGYJNbB8=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p align=\"justify\">\n        <sup>1<\/sup> May, M. Eleven clinical trials that will shape medicine in 2026.\u00a0<em>Nat Med<\/em>\u00a0<strong>31<\/strong>, 3943\u20133947 (2025)<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDE4NSM3MzI3ODk4IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjRiZThjZTYtODljZi00M2RkLTgxMGEtNGZhMDNiMTI4MjYwLTExMDIyMjktMjAyNS0xMi0xOC1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID BriaCell\u2019s Phase 3 clinical trial in metastatic breast cancer featured as \u201cclinical trial to watch in 2026\u201d BriaCell anticipates reporting top line data as early as H1-2026 PHILADELPHIA and VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its Phase 3 Bria-IMT\u2122 clinical trial in metastatic breast cancer has been prominently and independently featured in the Nature Medicine Year In Review\u2019s publication, \u201cEleven clinical trials &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-920889","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID BriaCell\u2019s Phase 3 clinical trial in metastatic breast cancer featured as \u201cclinical trial to watch in 2026\u201d BriaCell anticipates reporting top line data as early as H1-2026 PHILADELPHIA and VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its Phase 3 Bria-IMT\u2122 clinical trial in metastatic breast cancer has been prominently and independently featured in the Nature Medicine Year In Review\u2019s publication, \u201cEleven clinical trials &hellip; Continue reading &quot;\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-18T14:03:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDE4NSM3MzI3ODk4IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine\",\"datePublished\":\"2025-12-18T14:03:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\\\/\"},\"wordCount\":819,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNDE4NSM3MzI3ODk4IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\\\/\",\"name\":\"\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNDE4NSM3MzI3ODk4IzIwOTA2NTg=\",\"datePublished\":\"2025-12-18T14:03:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNDE4NSM3MzI3ODk4IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNDE4NSM3MzI3ODk4IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/","og_locale":"en_US","og_type":"article","og_title":"\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine - Market Newsdesk","og_description":"Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID BriaCell\u2019s Phase 3 clinical trial in metastatic breast cancer featured as \u201cclinical trial to watch in 2026\u201d BriaCell anticipates reporting top line data as early as H1-2026 PHILADELPHIA and VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its Phase 3 Bria-IMT\u2122 clinical trial in metastatic breast cancer has been prominently and independently featured in the Nature Medicine Year In Review\u2019s publication, \u201cEleven clinical trials &hellip; Continue reading \"\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-18T14:03:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDE4NSM3MzI3ODk4IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine","datePublished":"2025-12-18T14:03:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/"},"wordCount":819,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDE4NSM3MzI3ODk4IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/","name":"\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDE4NSM3MzI3ODk4IzIwOTA2NTg=","datePublished":"2025-12-18T14:03:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDE4NSM3MzI3ODk4IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDE4NSM3MzI3ODk4IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"\u201cEleven clinical trials that will shape medicine in 2026\u201d \u2013 BriaCell Phase 3 Trial Featured in Nature Medicine"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/920889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=920889"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/920889\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=920889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=920889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=920889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}